AML Management Without Borders: Advancing Novel Combinations through Academic-Community Collaboration

Earn up to 1.0 AMA PRA Credit
About the Program
Overview
Learning Objectives
CME/ Information
Faculty and Disclosures
Instructions

Program Overview

AML Without Borders: Academic–Community Co-Management Solutions for Guideline Implementation is a two-session, CME-certified virtual learning collaborative designed to strengthen community–academic partnerships in acute myeloid leukemia (AML) care. Conducted over one week, the series combines concise Flash Talks and interactive Tumor Boards to address key challenges in diagnosis, molecular risk stratification, and non-intensive therapy selection for chemotherapy-ineligible patients.

Participants gain practical insights from expert faculty and apply evidence-based strategies through real-world case discussions. Following the live sessions, faculty-moderated, HIPAA-compliant community boards remain open for six weeks, fostering continued peer consultation, mentorship, and knowledge exchange. This model ensures sustained engagement and performance improvement, equipping community hematologists and oncologists to deliver guideline-concordant AML care across diverse practice settings.

Target Audience

This educational program is directed toward medical oncologists, hematologists, and pathologists. fellows, researchers, nurses, nurse practitioners, physician assistants, and other healthcare professionals interested in the treatment of patients with AML in the community and academic setting.  

Supporter Acknowledgement

This educational activity is supported by an independent educational grant from Kura Oncology.

Learning Objectives

Upon completion of this activity, the participant should be able to:
  • Participate in virtual tumor boards and case discussions with academic specialists  
  • Interpret molecular/cytogenetic results to classify AML risk accurately and select novel combination therapies  
  • Implement appropriate novel combination treatment options for AML patients based on current guidelines and clinical trial data 
  • Develop practice-specific implementation plans for novel combination AML care in frontline and relapse-refractory settings 

Accredited Provider

This activity is jointly provided by Global Education Group and Iridium Continuing Education.

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Iridium. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Global Education Group designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Faculty, Staff, and Planners’ Disclosures

Global
The planners and managers at Global Education Group have no relevant financial relationships to disclose.

Iridium
The planners and managers at Iridium have no relevant financial relationships to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global and Iridium do not recommend the use of any agent outside of the labeled indications.The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosures of Relevant Financial Relationship(s)

​Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:
Mathew Angelos, MD, PhD
Assistant Professor of Medicine
UCHealth Blood Disorders & Cell Therapies Center
University of Colorado Anschutz Medical Campus
Aurora, CO
Disclosures:
Consulting Fee (e.g., Advisory Board): Gamida Cell, Novartis

Instructions to Receive Credit

In order to receive credit for this activity, the participant must: 

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Participate by attending flash talks and tumor boards.
  • Complete the posttest with a score of 70% or higher
  • Complete the evaluation

A statement of credit will be issued within four weeks of receipt of a completed activity evaluation form.

Fee Information and Refund/Cancellation Policy

There is no fee for this educational activity.

Contact Information

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com

System Requirements

System requirements
AML Without Borders brings together academic specialists and community clinicians for interactive, case-based mentorship designed to support real-world treatment planning in acute myeloid leukemia. As novel combinations and targeted agents evolve rapidly, clinicians are navigating new considerations in molecular interpretation, therapy sequencing, toxicity management, and coordinating care across settings.

Through concise flash talks, expert tumor boards, and open Q&A, participants will gain practical, evidence-informed strategies to apply directly in practice. All discussions are HIPAA compliant, collaborative, and focused on improving continuity of care for patients with AML.

To secure your place and receive session reminders, please be sure to click the green "Register for free" button.

Target Audience

This educational program is directed toward medical oncologists, hematologists, pathologists, fellows, researchers, nurses, nurse practitioners, physician assistants, and other healthcare professionals interested in the treatment of patients with AML in the community and academic setting.  

Dates

This educational activity is supported by an independent educational grant from
Kura Oncology.

Maximum Credit Amount: 1.0

Credit Type: ACCME
Release: 12/1/2025
Expiration: 12/3/2025